The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.00
Bid: 40.00
Ask: 42.00
Change: -1.00 (-2.38%)
Spread: 2.00 (5.00%)
Open: 42.00
High: 42.00
Low: 41.00
Prev. Close: 42.00
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Alusid - £125,000 backing from UK Future Fund

10 Nov 2020 07:00

RNS Number : 7394E
Frontier IP Group plc
10 November 2020
 

REACH

AIM: FIPP

10 November 2020

 

Frontier IP Group plc

("Frontier IP" or the "Group")

 

 

Portfolio news - Alusid gains £125,000 backing from UK Government Future Fund as part of £250,000 fund raising

 

 

Frontier IP, a specialist in commercialising intellectual property, today notes the following announcement from portfolio company Alusid Limited ("Alusid" or the "Company") that it has raised £250,000 via a convertible loan, including a £125,000 investment from the UK government's Future Fund.

 

The investment from the Future Fund, which was established to support the UK's innovative businesses currently affected by COVID-19, has been matched by £100,000 from the Group and £25,000 from a private investor. Frontier IP holds a 35.6 per cent equity stake in the Company.

 

The funding will be used to accelerate development and commercial scale up of Alusid's patented technology to create beautiful, premium-quality tiles and other surfaces from recycled ceramic, glass and other industrial waste. Earlier this year, the Company completed a successful pilot on industry-standard mass production equipment, which will transform capacity from 4,000m2 a year to 1,000m2 a day.

 

Alusid's customers include COS, part of H&M, and its tiles are distributed by Parkside Architectural Tiles, the commercial arm of retailer Topps Tiles plc.

 

Other clients include Pret-a-Manger, Harrods, Selfridges, Nando's and Amazon UK, all of which have been secured by UK distributor Panaz.

 

Frontier IP Chief Executive Officer, Neil Crabb, said: "This investment from the Future Fund will be invaluable in supporting Alusid's move into mass production. The scale up opens up new markets for the Company and I am confident that the combination of green technology and high-quality products will prove very attractive to potential industry partners."

 

 

 

Alusid statement begins:

 

 

10 November 2020 Alusid Limited ("Alusid" or the "Company") today announces it has successfully raised £250,000 via a convertible loan, including a £125,000 investment from the UK government's Future Fund, established to support innovative businesses through the COVID-19 pandemic.

 

The Future Fund's investment has been matched by Frontier IP Group, a specialist in commercialising intellectual property, and a private investor. They have invested £100,000 and £25,000 respectively.

 

The convertible loan will be used to support the scale up of Alusid's patented technology to create beautiful, premium-quality tiles and other surfaces out of recycled ceramic, glass and other industrial waste.

 

Alusid has been hand making tiles using a batch process at its facility in Preston, where current capacity is 4,000m2 a year. However, earlier this year, the company successfully completed a pilot run on industry standard mass production equipment. Once this is running commercially, the Company will be able to make 1,000m2 tiles a day, a move opening up new markets.

 

Customers include COS, part of H&M, and a bespoke tile range, Sequel Vibe, is also distributed by Parkside Architectural Tiles, the commercial arm of Topps Tiles. Alusid has also supplied Pret-a-Manger, Harrods, Selfridges, Nando's and Amazon UK, all of which have been secured by distributor Panaz.

 

The Company has also won numerous industry awards. Sequel Vibe was highly commended in the Best Product Design category at 2019's Blueprint Awards and named Wall Tile of the Year at 2020's Tile Association awards.

 

 

 

Alusid co-founder and Chief Executive Officer, Dr Alasdair Bremner, said: "This investment, made possible by the Future Fund, will enable Alusid to launch the world's first retail tile made from 95 per cent recycled material in the New Year. Although we expect disruption from the COVID-19 pandemic to continue, this investment ensures we are in a strong position to deliver on our ambitious plans."

 

 

 

Alusid statement ends

 

ENQUIRIES

 

Frontier IP Group Plc

T: 020 7332 2338

Neil Crabb, Chief Executive

Andrew Johnson, Communications & Investor Relations

Company website: www.frontierip.co.uk

neil@frontierip.co.uk

M: 07464 546 025

Allenby Capital Limited (Nominated Adviser)

T: 0203 328 5656

Nick Athanas / James Hornigold

 

 

 

ABOUT THE FUTURE FUND

The Future Fund will support the UK's innovative businesses currently affected by Covid-19. These businesses have been unable to access other government business support programmes, such as CBILS, because they are either pre-revenue or pre-profit and typically rely on equity investment. Initially, £250 million was made available by the government for investment through the scheme, to be matched by private investors, with the Treasury making clear the amount could be increased if needed. Due to the popularity of the Fund, more funding is being made available. Developed by the government and delivered by the British Business Bank, the Future Fund launched for applications in May and is open until the end of January 2021.

ABout frontier IP

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

About Reach announcements

 

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFSMFWUESSELF
Date   Source Headline
2nd May 20247:00 amRNSFrontier IP announces stake in DiaGen
17th Apr 20241:59 pmRNSHolding(s) in Company
12th Apr 20247:00 amRNSAppointment of Chief Financial Officer
2nd Apr 202412:44 pmRNSHolding(s) in Company
14th Mar 20247:00 amRNSUnaudited Half Year Results
4th Mar 20241:40 pmRNSHolding(s) in Company
29th Feb 20243:12 pmRNSSale of shares in Exscientia
30th Jan 202411:45 amRNSHolding(s) in Company
22nd Jan 20247:00 amRNSOctopus invest in Alusid as part of equity funding
29th Dec 202312:00 pmRNSTotal Voting Rights
19th Dec 20234:46 pmRNSHolding(s) in Company
15th Dec 20236:12 pmRNSReplacement - Result of AGM and Directorate Change
15th Dec 20232:07 pmRNSResult of AGM and Directorate Change
13th Dec 20237:00 amRNSPortfolio news - The Vaccine Group
11th Dec 20237:00 amRNSHolding(s) in Company
30th Nov 20235:00 pmRNSTotal Voting Rights
30th Nov 20237:00 amRNSExercise of Options & Director/PDMR Shareholdings
28th Nov 20237:00 amRNSBoard Change
21st Nov 20237:00 amRNSPosting of Annual Report and Notice of AGM
9th Nov 20235:27 pmRNSHolding(s) in Company
3rd Nov 20237:05 amRNSGrant of options
1st Nov 20235:48 pmRNSExercise of Options & PDMR Shareholdings & TVR
31st Oct 20237:01 amRNSBoard changes
31st Oct 20237:00 amRNSFinal results for the year ended 30 June 2023
23rd Oct 20237:00 amRNSNew portfolio company Deakin Bio-Hybrid Materials
12th Oct 20232:05 pmRNSHolding(s) in Company
21st Sep 20237:00 amRNSExscientia announces collaboration with Merck
14th Sep 20235:21 pmRNSHolding(s) in Company
14th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
11th Sep 20237:00 amRNSPortfolio news – Pulsiv appoints Chairman and CPO
8th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
10th Aug 20238:45 amRNSPortfolio news – Fieldwork Robotics
24th Jul 20237:00 amRNSPortfolio news – CamGraPhIC loan facility
20th Jul 20235:18 pmRNSHolding(s) in Company
1st Jun 20237:00 amRNSSale of shares in Exscientia
26th May 20236:06 pmRNSHolding(s) in Company
9th May 20237:00 amRNSTopps Tiles launches first Alusid made tile range
21st Apr 20234:00 pmRNSDirectorate Change
20th Apr 20235:26 pmRNSHolding(s) in Company
27th Mar 20235:17 pmRNSHolding(s) in Company
17th Mar 20232:46 pmRNSGrant of options
15th Mar 20237:00 amRNSBoard changes
15th Mar 20237:00 amRNSUnaudited Half Year Results
30th Jan 20237:00 amRNSAlusid in collaboration with Imerys
9th Jan 20237:00 amRNSCelerum appoints David Gladding as CEO
9th Dec 20224:08 pmRNSResult of AGM
7th Dec 20221:25 pmEQSThe Vaccine Group completes two deadly disease vaccination projects
6th Dec 20227:00 amRNSFrontier IP to host Portfolio Demo Day
5th Dec 20227:00 amRNSThe Vaccine Group completes Lassa fever project
2nd Dec 20227:00 amRNSThe Vaccine Group completes vaccine project

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.